Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

BackgroundThe phase 3 clinical trial KEYNOTE-426 suggested a higher efficacy regarding overall survival (OS) and progression-free survival (PFS) of pembrolizumab+axitinib compared to sunitinib as a first-line treatment for patients with advanced renal cell carcinoma. In this analysis, the potential...

Full description

Bibliographic Details
Main Authors:	Nicolas S. H. Xander, W. Edward Fiets, Carin A. Uyl-de Groot
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Oncology
Subjects:	cost-effectiveness budget impact pembrolizumab axitinib sunitinib renal cell carcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1205700/full

Similar Items

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
by: Koshiro Nishimoto, et al.
Published: (2022-05-01)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
by: Chau V, et al.
Published: (2020-08-01)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
by: Gaetano Facchini, et al.
Published: (2019-08-01)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
by: Shinji Tamada, et al.
Published: (2022-11-01)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
by: Yuki Katsumata, et al.
Published: (2021-10-01)

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
by: Andrea Boutros, et al.
Published: (2022-12-01)

Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report
by: Kawasoe C, et al.
Published: (2023-10-01)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
by: Viktor Grünwald, et al.
Published: (2023-08-01)

Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
by: Yoshifumi Kadono, et al.
Published: (2023-05-01)

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
by: Viktor Grünwald, et al.
Published: (2024-03-01)

A case of an advanced renal collecting duct carcinoma in which initial therapeutic effect was achieved with pembrolizumab plus axitinib
by: Yuichiro Atagi, et al.
Published: (2024-01-01)

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
by: Yun Beom Sang, et al.
Published: (2022-12-01)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
by: Marco Stellato, et al.
Published: (2023-01-01)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
by: Meng‐Jia Song, et al.
Published: (2021-01-01)

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
by: B. Ya. Alekseev, et al.
Published: (2021-06-01)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
by: Remziye Zaim, et al.
Published: (2022-06-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
by: Remziye Zaim, et al.
Published: (2023-03-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
by: Dong Hyuk Kang, et al.
Published: (2023-05-01)

Experience of successful use of axitinib in therapy of metastatic renal cell carcinoma after immunotargeted therapy
by: A. A. Rumyantsev
Published: (2021-12-01)

Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian “Real-Word” SAX study
by: Carmine D'Aniello, et al.
Published: (2016-09-01)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
by: Peiyao Lu, et al.
Published: (2020-05-01)

How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
by: Lytske Bakker, et al.
Published: (2021-11-01)

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
by: Carin A. Uyl-de Groot, et al.
Published: (2020-08-01)

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
by: Toon van der Gronde, et al.
Published: (2017-01-01)

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
by: Yi Hsuan Chen, et al.
Published: (2023-01-01)

Case Report: Early 68Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases
by: Emmanuel Seront, et al.
Published: (2021-12-01)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
by: Carin A. Uyl-de Groot, et al.
Published: (2018-07-01)

Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma
by: Jindrich Kopecky, et al.
Published: (2018-11-01)

Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
by: Yousef Zakharia, et al.
Published: (2022-05-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
by: Jane L. Roberts, et al.
Published: (2021-09-01)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01)

Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome
by: Chrissy H. Y. van Beurden-Tan, et al.
Published: (2022-05-01)

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
by: Masatoshi Eto, et al.
Published: (2023-03-01)

A case of complete response to avelumab plus axitinib combination therapy for metastatic clear cell renal cell carcinoma in a kidney undergoing dialysis
by: Ei Shiomi, et al.
Published: (2024-03-01)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
by: Valentina Giudice, et al.
Published: (2020-12-01)